Compare KRNY & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNY | PRME |
|---|---|---|
| Founded | 1884 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.5M | 536.4M |
| IPO Year | 2014 | 2022 |
| Metric | KRNY | PRME |
|---|---|---|
| Price | $9.48 | $3.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $9.25 | $7.56 |
| AVG Volume (30 Days) | 489.8K | ★ 2.8M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | ★ 130.22 | 18.18 |
| EPS | ★ 0.46 | N/A |
| Revenue | $2,580,000.00 | ★ $4,632,000.00 |
| Revenue This Year | $3.89 | $7.06 |
| Revenue Next Year | $17.52 | $47.01 |
| P/E Ratio | $20.72 | ★ N/A |
| Revenue Growth | 36.00 | ★ 55.28 |
| 52 Week Low | $5.98 | $2.67 |
| 52 Week High | $9.82 | $6.94 |
| Indicator | KRNY | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 51.65 |
| Support Level | $9.05 | $3.16 |
| Resistance Level | $9.74 | $3.60 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 46.40 | 85.71 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.